Active — Not RecruitingNot Applicable

TME Alteration in HER2 Positive Breast Cancer

South Korea30 participantsStarted 2024-07-19

Plain-language summary

Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant cancer therapy and surgery for curative purposes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients Exclusion criteria If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study

What they're measuring

tumor microenvironment alteration

Timeframe: 6 months

Trial details

NCT IDNCT06533670

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07-19

View on ClinicalTrials.gov More Breast Cancer trials